Tenax Therapeutics to Host KOL Event: "LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study"
Stock Information for Tenax Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.